Imprimis Pharmaceuticals, Inc. (NASDAQ:IMMY) hit a new 52-week low on Friday . The stock traded as low as $1.62 and last traded at $1.61, with a volume of 213,471 shares trading hands. The stock had previously closed at $1.79.

IMMY has been the subject of several recent research reports. Zacks Investment Research raised Imprimis Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Wednesday, July 12th. ValuEngine cut Imprimis Pharmaceuticals from a “sell” rating to a “strong sell” rating in a research note on Tuesday, May 16th.

The firm’s 50 day moving average is $2.23 and its 200 day moving average is $3.07. The company’s market capitalization is $32.71 million.

Imprimis Pharmaceuticals (NASDAQ:IMMY) last released its quarterly earnings results on Thursday, August 10th. The specialty pharmaceutical company reported $0.06 EPS for the quarter, beating analysts’ consensus estimates of ($0.23) by $0.29. The business had revenue of $6.86 million during the quarter. Imprimis Pharmaceuticals had a negative return on equity of 242.66% and a negative net margin of 57.07%. Equities analysts expect that Imprimis Pharmaceuticals, Inc. will post ($0.86) EPS for the current year.

In other Imprimis Pharmaceuticals news, Director Robert J. Kammer sold 10,000 shares of the company’s stock in a transaction that occurred on Monday, July 17th. The stock was sold at an average price of $3.05, for a total transaction of $30,500.00. Following the completion of the transaction, the director now owns 1,059,827 shares of the company’s stock, valued at approximately $3,232,472.35. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Corporate insiders own 12.55% of the company’s stock.

Institutional investors and hedge funds have recently added to or reduced their stakes in the business. Apollo Management Holdings L.P. bought a new position in Imprimis Pharmaceuticals during the 1st quarter valued at approximately $417,000. Vanguard Group Inc. raised its position in Imprimis Pharmaceuticals by 78.2% during the 2nd quarter. Vanguard Group Inc. now owns 451,226 shares of the specialty pharmaceutical company’s stock valued at $1,444,000 after purchasing an additional 198,068 shares during the last quarter. Bank of New York Mellon Corp raised its position in Imprimis Pharmaceuticals by 60.7% during the 2nd quarter. Bank of New York Mellon Corp now owns 35,606 shares of the specialty pharmaceutical company’s stock valued at $114,000 after purchasing an additional 13,455 shares during the last quarter. KCG Holdings Inc. bought a new position in Imprimis Pharmaceuticals during the 1st quarter valued at approximately $130,000. Finally, Wealthsource Partners LLC bought a new position in Imprimis Pharmaceuticals during the 1st quarter valued at approximately $125,000. 17.82% of the stock is owned by institutional investors and hedge funds.

COPYRIGHT VIOLATION WARNING: “Imprimis Pharmaceuticals, Inc. (IMMY) Reaches New 52-Week Low at $1.62” was reported by Daily Political and is owned by of Daily Political. If you are reading this piece of content on another site, it was stolen and reposted in violation of United States & international trademark and copyright laws. The original version of this piece of content can be read at https://www.dailypolitical.com/2017/09/08/imprimis-pharmaceuticals-inc-immy-reaches-new-52-week-low-at-1-62.html.

About Imprimis Pharmaceuticals

Imprimis Pharmaceuticals, Inc (Imprimis) is engaged in the development, production and dispensing of compounded pharmaceuticals. The Company operates through the business of developing drug therapies and providing such therapies through sterile and non-sterile pharmaceutical compounding services segment.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.